Linari Medical

Linari Medical operates in the medical-device and digital-rehabilitation segment, addressing neurovisual, cognitive, and sensory-motor rehabilitation through a combination of equipment and telemedicine. AvDesk® is described as combining multisensory stimulation with remote monitoring; the company also offers a portable home-use version, a clinic-oriented version, and a cloud platform for managing therapy remotely. Its stated differentiation is the integration of hardware, software, specialist-supervised home pathways, and tools for observing patient gaze and movement. The company also points to clinical research with the IRCCS Stella Maris Foundation and collaboration with clinicians, as well as a network of more than 50 centers and specialists in Italy and more than 1,000 people completing an AvDesk pathway since 2019. With a reported team size of 1–10 and one pre-seed round of approximately $118,861, Linari Medical appears to be a small, specialized operator rather than a broadly scaled medical-device platform.

Founded in 2018, Linari Medical has developed a focused portfolio spanning AvDesk®, its cloud platform, and remote visual, orthoptic, and speech-therapy services. CEO Caterina Stimola has held the role since December 2018, providing continuity from the company’s early operating period. The clearest financing inflection point is the Feb 3, 2023 pre-seed round: €110,000, approximately $118,861, led by VITA Accelerator. No later funding round or hiring announcement is identified in the available profile, and the reported employee band remains 1–10, so evidence of organizational scaling is limited. The company’s product range suggests an expansion from a core rehabilitation device toward home-based use and digitally managed care pathways. Patent-related activity dated Jul 23, 2025, covering self-administered audiovisual stimulation and speech therapies, points to continued development of at-home treatment approaches; earlier 2023 entries concern monitoring user conditions and movement. This indicates product and intellectual-property development, but not by itself commercial growth.